IDH1-mutated relapsed or refractory AML: current challenges and future prospects
Blood and Lymphatic Cancer: Targets and Therapy · 2019
DOI: 10.2147/blctt.s177913 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood and Lymphatic Cancer: Targets and Therapy, 2019. Verfasst von Juan Eduardo Megías-Vericat und 3 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Farmacia, Área del Medicamento, Hospital Universitari i Politècnic La Fe, Valencia, Spain. Die Arbeit wurde bisher 31-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Servicio de Farmacia, Área del Medicamento, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
- Servicio de Hematología y Hemoterapia, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
- CIBERONC, Instituto Carlos III, Madrid, Spain.
ORCID-Profile: Juan Eduardo Megías-Vericat, Pau Montesinos
Zitieren
APA
Megías-Vericat, J. E., Ballesta-López, O., Barragán, E., & Montesinos, P. (2019). IDH1-mutated relapsed or refractory AML: current challenges and future prospects. Blood and Lymphatic Cancer: Targets and Therapy. https://doi.org/10.2147/blctt.s177913
Vancouver
Megías-Vericat JE, Ballesta-López O, Barragán E, Montesinos P. IDH1-mutated relapsed or refractory AML: current challenges and future prospects. Blood and Lymphatic Cancer: Targets and Therapy. 2019. doi:10.2147/blctt.s177913
BibTeX
@article{MegasVericat2019,
author = {Megías-Vericat, Juan Eduardo and Ballesta-López, Octavio and Barragán, Eva and Montesinos, Pau},
title = {IDH1-mutated relapsed or refractory AML: current challenges and future prospects},
journal = {Blood and Lymphatic Cancer: Targets and Therapy},
year = {2019},
doi = {10.2147/blctt.s177913}
}
EUVIMED